TY - CHAP M1 - Book, Section TI - Using Plasma and Plasma Component Therapy A1 - Levy, Jerrold H. A1 - Shaz, Beth A2 - Kaushansky, Kenneth A2 - Prchal, Josef T. A2 - Burns, Linda J. A2 - Lichtman, Marshall A. A2 - Levi, Marcel A2 - Linch, David C. PY - 2021 T2 - Williams Hematology, 10e AB - SUMMARYPlasma and plasma component therapy includes fresh frozen plasma, plasma, and cryoprecipitate. Although plasma is used extensively in many clinical applications that include coagulopathy and coagulation factor correction and surgical and traumatic bleeding resuscitation, data supporting its efficacy are limited. Plasma-based transfusions also pose multiple risks, including circulatory overload and transfusion-related acute lung injury. Indications for plasma and cryoprecipitate vary between countries, and the use of factor concentrates including prothrombin complex concentrates and fibrinogen are increasingly used as potential replacements. Strategies are available for pathogen reduction for plasma and plasma products, but additional cost and loss of factors are considerations for their use. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/11/01 UR - hemonc.mhmedical.com/content.aspx?aid=1178757552 ER -